As mentioned above, anti-seizure treatment using EKC (or upregulating endogenous Kcna1 transcription) has been previously reported in models of temporal lobe epilepsy.15,16 The present study adds FCD II to the range of epilepsy models in which gene therapy with CAMK2A-EKC is effective. This evidence concerns the gene CAMK2A and temporal lobe epilepsy.